8-KLeadership Changes

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Feb 14, 2014)

Filed February 14, 2014For Securities:BMYCELG-RIBMYMP

Summary

This Form 8-K filing from Bristol-Myers Squibb Company (BMY) on February 14, 2014, details the separation agreement with former executive Beatrice Cazala. Ms. Cazala's employment is set to terminate on June 9, 2014, after declining a position in France. The agreement outlines severance payments, continued benefits, and the handling of stock and incentive awards. This event is primarily an administrative change, and the financial impact appears to be managed through a structured separation process. Investors should note the specific terms of the separation, including the approximately $3 million in cash severance and other benefits provided to Ms. Cazala. The agreement also includes standard provisions such as a general release of claims by Ms. Cazala and non-disparagement covenants. The company's engagement with Ms. Cazala as an active employee in the U.S. until her separation date, while continuing to work through the transition, is also a key aspect of this filing.

Key Highlights

  • 1Beatrice Cazala, an executive officer, will cease employment with Bristol-Myers Squibb Company effective June 9, 2014.
  • 2Ms. Cazala declined a offered position in France, leading to the termination of her French employment contract.
  • 3The company and Ms. Cazala have entered into a Settlement Agreement and General Release, effective February 14, 2014.
  • 4Ms. Cazala will receive approximately $3 million in cash severance, pension benefits, and partially subsidized retiree medical benefits.
  • 5She will remain an active employee in the U.S. at her current salary until her separation date and continue to be eligible for applicable benefit plans.
  • 6Ms. Cazala will be eligible for her 2013 annual incentive award and continued vesting of previously awarded unvested stock units, provided performance thresholds are met.
  • 7The agreement includes confidentiality and non-disparagement covenants, as well as a six-month non-compete restriction for Ms. Cazala post-separation.

Frequently Asked Questions

This 8-K filing is primarily to report on the separation agreement between Bristol-Myers Squibb Company and its executive Beatrice Cazala, detailing the terms and conditions of her departure.

Ms. Cazala is entitled to approximately $3 million in cash severance, pension benefits, and access to partially subsidized retiree medical benefits. Additionally, she will receive a $1.5 million lump sum settlement payment and $185,000 for expenses.

Ms. Cazala will continue to be eligible for the vesting of previously awarded but unvested stock unit awards in accordance with plan documents. She is also eligible for pro rata distributions from restricted stock unit and long-term incentive awards outstanding for more than a year, assuming performance thresholds are met. Awards outstanding for less than one year will lapse.

Yes, Ms. Cazala has agreed to confidentiality and non-disparagement obligations. She is also restricted from engaging in certain activities competitive with the company for a period of six months after her separation date.